Compare ASPI & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | TNYA |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | 70 |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.1M | 169.9M |
| IPO Year | 2022 | 2021 |
| Metric | ASPI | TNYA |
|---|---|---|
| Price | $5.26 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $12.00 | $5.33 |
| AVG Volume (30 Days) | 3.7M | ★ 4.9M |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,849,000.00 | N/A |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $0.39 |
| 52 Week High | $14.49 | $2.35 |
| Indicator | ASPI | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 49.77 |
| Support Level | $5.13 | $0.65 |
| Resistance Level | $5.88 | $0.82 |
| Average True Range (ATR) | 0.42 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 25.81 | 25.77 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.